Interim decisions and reasons for decisions by delegates of the Secretary to the Department of Health and Ageing

May 2013 invitation for further submissions

Notice under subsections 42ZCZP of the Therapeutic Goods Regulations 1990 (the Regulations)

A delegate of the Secretary to the Department of Health and Ageing hereby gives notice of delegates’ interim decisions under subsection 42ZCZP of the Therapeutic Goods Regulations 1990 (the Regulations).


Further submissions must be relevant to the proposed amendment, must address a matter mentioned in section 52E of the Therapeutic Goods Act 1989 and be received by the closing date (6 June 2013).

Further submissions from parties other than those who made a valid submission in response to the original invitation or the applicant, or those received after the closing date, need not be considered by the delegate.

Please note that all valid submissions received on or before the closing date will be published following removal of confidential information. It is up to the person making the submission to highlight any information which they wish to be considered as confidential. Material claimed to be commercial-in-confidence will be considered against the guidelines for the use and release of confidential information set out in Chapter 6 of the Scheduling Policy Framework (SPF), issued by the National Coordinating Committee on Therapeutic Goods. The SPF is accessible at [www.tga.gov.au/industry/scheduling-spf.htm](http://www.tga.gov.au/industry/scheduling-spf.htm).

Persons making submissions are strongly encouraged to lodge submissions in electronic format (word or unsecured PDF preferred) via the email address provided below. Submissions, preferably in electronic format, should be made to:

Medicines and Poisons Scheduling Secretariat (MDP88)
GPO Box 9848
CANBERRA ACT 2601
e-mail SMP@health.gov.au Facsimile 02-6289 2650

The closing date for further submissions is 6 June 2013.
Table of contents

Glossary 3

Interim decisions on proposal referred to an advisory committee 8

1. March 2013 meeting of the Advisory Committee on Chemicals Scheduling (ACCS) – ACCS # 7
   1.1 ABAMECTIN 8
   1.2 CARBONYL SULFIDE 10
   1.3 CHLORFENAPYR 12
   1.4 EUBACTERIUM SP 14
   1.5 PYROXASULFONE 17
   1.6 SULFOXAFLORE 19

2. March 2013 meeting of the joint Advisory Committee on Chemicals Scheduling (ACCS) and the Advisory Committee on Medicines Scheduling – ACCS & ACMS # 5 22
   2.1 ADRENALINE, BUPIVACAINE AND LIGNOCAINE 22
   2.2 TYLOSIN 25
   2.3 TERMINOLOGY 28

3. March 2013 meeting of the Advisory Committee on Medicines Scheduling – ACMS # 8 30
   3.1 BENZODIAZEPINES 30
   3.2 DICLOFENAC 33
   3.3 HYDROCORTISONE AND HYDROCORTISONE ACETATE 35
   3.4 LISDEXAMFETAMINE 38
   3.5 NABIXIMOLS 40
   3.6 Oseltamivir 42
## Glossary

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAN</td>
<td>Australian Approved Name</td>
</tr>
<tr>
<td>AC</td>
<td>Active constituent</td>
</tr>
<tr>
<td>ACCC</td>
<td>Australian Competition and Consumer Commission</td>
</tr>
<tr>
<td>ACCM</td>
<td>Advisory Committee on Complementary Medicines (formerly Complementary Medicine Evaluation Committee [CMEC])</td>
</tr>
<tr>
<td>ACNM</td>
<td>Advisory Committee on Non-prescription Medicines (formerly Medicines Evaluation Committee [MEC])</td>
</tr>
<tr>
<td>ACPM</td>
<td>Advisory Committee on Prescription Medicines (formerly Australian Drug Evaluation Committee [ADEC])</td>
</tr>
<tr>
<td>ACSOM</td>
<td>Advisory Committee on the Safety of Medicines (formerly Adverse Drug Reactions Advisory Committee [ADRAC])</td>
</tr>
<tr>
<td>ADEC</td>
<td>Australian Drug Evaluation Committee (now Advisory Committee on Prescription Medicines [ACPM])</td>
</tr>
<tr>
<td>ADI</td>
<td>Acceptable daily intake</td>
</tr>
<tr>
<td>ADRAC</td>
<td>Adverse Drug Reactions Advisory Committee (now Advisory Committee on the Safety of Medicines [ACSOM])</td>
</tr>
<tr>
<td>AHMAC</td>
<td>Australian Health Ministers' Advisory Council</td>
</tr>
<tr>
<td>APVMA</td>
<td>Australian Pesticides and Veterinary Medicines Authority</td>
</tr>
<tr>
<td>AQIS</td>
<td>Australian Quarantine and Inspection Service</td>
</tr>
<tr>
<td>ARfD</td>
<td>Acute reference dose</td>
</tr>
<tr>
<td>ASCC</td>
<td>Australian Safety and Compensation Council</td>
</tr>
<tr>
<td>ASMI</td>
<td>Australian Self-Medication Industry</td>
</tr>
<tr>
<td>ARTG</td>
<td>Australian Register of Therapeutic Goods</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Name</td>
</tr>
<tr>
<td>--------------</td>
<td>------</td>
</tr>
<tr>
<td>CAS</td>
<td>Chemical Abstract Service</td>
</tr>
<tr>
<td>CHC</td>
<td>Complementary Healthcare Council of Australia</td>
</tr>
<tr>
<td>CMEC</td>
<td>Complementary Medicine Evaluation Committee (now Advisory Committee on Complementary Medicines [ACCM])</td>
</tr>
<tr>
<td>CMI</td>
<td>Consumer Medicine Information</td>
</tr>
<tr>
<td>COAG</td>
<td>Councils of Australian Governments</td>
</tr>
<tr>
<td>CRC</td>
<td>Child-resistant closure</td>
</tr>
<tr>
<td>CTFAA</td>
<td>Cosmetic, Toiletry &amp; Fragrance Association of Australia</td>
</tr>
<tr>
<td>CWP</td>
<td>Codeine Working Party</td>
</tr>
<tr>
<td>DAP</td>
<td>Drafting Advisory Panel</td>
</tr>
<tr>
<td>ECRP</td>
<td>Existing Chemicals Review Program</td>
</tr>
<tr>
<td>EPA</td>
<td>Environmental Protection Authority</td>
</tr>
<tr>
<td>ERMA</td>
<td>Environmental Risk Management Authority (New Zealand)</td>
</tr>
<tr>
<td>FAISD</td>
<td>First Aid Instructions and Safety Directions</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration (United States)</td>
</tr>
<tr>
<td>FOI</td>
<td>Freedom of Information Act 1982</td>
</tr>
<tr>
<td>FSANZ</td>
<td>Food Standards Australia New Zealand</td>
</tr>
<tr>
<td>GHS</td>
<td>Globally Harmonised System for Classification and Labelling of Chemicals</td>
</tr>
<tr>
<td>GIT</td>
<td>Gastro-intestinal tract</td>
</tr>
<tr>
<td>GP</td>
<td>General practitioner</td>
</tr>
<tr>
<td>HCN</td>
<td>Health Communication Network</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Name</td>
</tr>
<tr>
<td>--------------</td>
<td>------</td>
</tr>
<tr>
<td>INN</td>
<td>International Non-proprietary Name</td>
</tr>
<tr>
<td>ISO</td>
<td>International Standards Organization</td>
</tr>
<tr>
<td>LC50</td>
<td>The concentration of a substance that produces death in 50% of a population of experimental organisms. Usually expressed as mg per litre (mg/L) as a concentration in air.</td>
</tr>
<tr>
<td>LD50</td>
<td>The concentration of a substance that produces death in 50% of a population of experimental organisms. Usually expressed as milligrams per kilogram (mg/kg) of body weight.</td>
</tr>
<tr>
<td>LOAEL</td>
<td>Lowest observed adverse effect level</td>
</tr>
<tr>
<td>LOEL</td>
<td>Lowest observed effect level</td>
</tr>
<tr>
<td>MCC</td>
<td>Medicines Classification Committee (New Zealand)</td>
</tr>
<tr>
<td>MEC</td>
<td>Medicines Evaluation Committee (now Advisory Committee on Non-prescription Medicines [ACNM])</td>
</tr>
<tr>
<td>MOH</td>
<td>Ministry of Health (New Zealand)</td>
</tr>
<tr>
<td>NCCTG</td>
<td>National Coordinating Committee on Therapeutic Goods</td>
</tr>
<tr>
<td>NDPSC</td>
<td>National Drugs and Poisons Schedule Committee</td>
</tr>
<tr>
<td>NHMRC</td>
<td>National Health and Medical Research Council</td>
</tr>
<tr>
<td>NICNAS</td>
<td>National Industrial Chemicals Notification &amp; Assessment Scheme</td>
</tr>
<tr>
<td>NOAEL</td>
<td>No observed adverse effect level</td>
</tr>
<tr>
<td>NOEL</td>
<td>No observable effect level</td>
</tr>
<tr>
<td>NOHSC</td>
<td>National Occupational Health &amp; Safety Commission</td>
</tr>
<tr>
<td>OCM</td>
<td>Office of Complementary Medicines</td>
</tr>
<tr>
<td>OCSEH</td>
<td>Office of Chemical Safety and Environmental Health (now Office of Chemical Safety [OCS])</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Name</td>
</tr>
<tr>
<td>--------------</td>
<td>------</td>
</tr>
<tr>
<td>OCS</td>
<td>Office of Chemical Safety (formerly Office of Chemical Safety and Environmental Health [OCSEH])</td>
</tr>
<tr>
<td>ODA</td>
<td>Office of Devices Authorisation</td>
</tr>
<tr>
<td>OMA</td>
<td>Office of Medicines Authorisation (formerly Office of Prescription and Non-prescription Medicines)</td>
</tr>
<tr>
<td>OOS</td>
<td>Out of session</td>
</tr>
<tr>
<td>OTC</td>
<td>Over-the-counter</td>
</tr>
<tr>
<td>PACIA</td>
<td>Plastics and Chemicals Industries Association</td>
</tr>
<tr>
<td>PAR</td>
<td>Prescription animal remedy</td>
</tr>
<tr>
<td>PBAC</td>
<td>Pharmaceutical Benefits Advisory Committee</td>
</tr>
<tr>
<td>PEC</td>
<td>Priority existing chemical</td>
</tr>
<tr>
<td>PGA</td>
<td>Pharmaceutical Guild of Australia</td>
</tr>
<tr>
<td>PHARM</td>
<td>Pharmaceutical Health and Rational Use of Medicines</td>
</tr>
<tr>
<td>PI</td>
<td>Product Information</td>
</tr>
<tr>
<td>PIC</td>
<td>Poisons Information Centre</td>
</tr>
<tr>
<td>PSA</td>
<td>Pharmaceutical Society of Australia</td>
</tr>
<tr>
<td>QCPP</td>
<td>Quality Care Pharmacy Program</td>
</tr>
<tr>
<td>QUM</td>
<td>Quality Use of Medicines</td>
</tr>
<tr>
<td>RFI</td>
<td>Restricted flow insert</td>
</tr>
<tr>
<td>SCCNFP</td>
<td>Scientific Committee on Cosmetic and Non-Food Products</td>
</tr>
<tr>
<td>SCCP</td>
<td>Scientific Committee on Consumer Products</td>
</tr>
<tr>
<td>STANZHA</td>
<td>States and Territories and New Zealand Health Authorities</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Name</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------------------------------------</td>
</tr>
<tr>
<td>SUSDP</td>
<td>Standard for the Uniform Scheduling of Drugs and Poisons</td>
</tr>
<tr>
<td>SUSMP</td>
<td>Standard for the Uniform Scheduling of Medicines and Poisons</td>
</tr>
<tr>
<td>SVT</td>
<td>First aid for the solvent prevails</td>
</tr>
<tr>
<td>TCM</td>
<td>Traditional chinese medicine</td>
</tr>
<tr>
<td>TGA</td>
<td>Therapeutic Goods Administration</td>
</tr>
<tr>
<td>TGC</td>
<td>Therapeutic Goods Committee</td>
</tr>
<tr>
<td>TGO</td>
<td>Therapeutic Goods Order</td>
</tr>
<tr>
<td>TTHWP</td>
<td>Trans-Tasman Harmonisation Working Party</td>
</tr>
<tr>
<td>TTMRA</td>
<td>Trans-Tasman Mutual Recognition Agreement</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>WP</td>
<td>Working party</td>
</tr>
<tr>
<td>WS</td>
<td>Warning statement</td>
</tr>
</tbody>
</table>
Interim decisions on proposal referred to an advisory committee

1. March 2013 meeting of the Advisory Committee on
Chemicals Scheduling (ACCS) – ACCS # 7

1.1 ABAMECTIN

Scheduling proposal

The Chemicals Scheduling Delegate considered a proposal to amend abamectin Schedule 6(a) entry to raise the cut-off from 2 to 4 per cent or less of abamectin in the Standard for the Uniform Scheduling of Medicines and Poisons.

The delegate referred the proposal to the Advisory Committee on Chemicals Scheduling (ACCS) for advice.

Scheduling history

In November 1984, the Poisons Schedule (Standing) Committee (PSC) considered scheduling of a 1 per cent avermectin B1 (a synonym for abamectin) injection to be used as an antiparasitic agent in animals. Based on toxicity, PSC decided to include this substance in Schedule 7. However, the PSC also noted the intent to only market a sealed container product for use with automated injection equipment and agreed to a Schedule 6 cut-off for such preparations when included in 10 mL or less injections.

In May 1992, the Drugs and Poisons Schedule Standing Committee agreed to a request to change the name of avermectin B1 in the schedule entries to abamectin, noting that this was the name approved by the Standards Association of Australia (now called Standards Australia).

In August 1994, the National Drugs and Poisons Schedule Committee (NDPSC) decided to include emulsifiable concentrate formulations containing abamectin at 18 g/L or less in Schedule 6.

In August 1995, NDPSC agreed to include ≤ 1 per cent abamectin for animal internal use in Schedule 5.

In June 2008, the NDPSC decided also to include slow-release plastic matrix ear tags for livestock use containing 1 g or less of abamectin in Schedule 6.

In October 2009, the NDPSC considered whether preparations for pesticidal use containing 0.0015 per cent or less of abamectin were consistent with the Schedule 5 criteria. It was agreed that although low concentration of abamectin were likely to be less hazardous, because insufficient data had been provided to allay the concern regarding the high acute oral, dermal and inhalation toxicity of abamectin, it was decided that the existing scheduling was appropriate, i.e. no changes.
Scheduling status

Abamectin is currently listed in Schedules 5, 6 and 7 and Appendix J.

Public pre-meeting submissions

No public submissions were received.

ACCS advice to the delegate

The ACCS recommended that the Schedule 6 cut-off for abamectin for pesticidal use be increased from 2 per cent to 4 per cent or less of abamectin.

The ACCS recommended an implementation date of 1 September 2013.

The matters under subsection 52E (1) of the *Therapeutic Goods Act 1989* considered relevant by the Committee included; (a) the risks and benefits of the use of a substance, (b) the purpose for which a substance is to be used and the extent of use of a substance, (d) the dosage, formulation, labelling, packaging and presentation of a substance and (f) any other matters.

The reasons for the recommendation comprised the following:

- the product was efficient against certain mites and insect pests of food crops.
- the risk of health effects associated with potential exposures have been adequately addressed.
- the MOE values were sufficient and a 1000-fold safety factor was considered to be protective of all toxicological findings.

Delegate's consideration

The delegate considered the following in regards to this proposal:

- the evaluation report (not publically available);
- scheduling application;
- ACCS advice;
- section 52E of the *Therapeutic Goods Act 1989*;
- scheduling factors\(^1\); and
- other relevant information.

Delegate's interim decision

The delegate decided to accept the ACCS advice and to increase the Schedule cut-off to 4 per cent.

The proposed implementation date for this decision is 1 September 2013.

The relevant matters considered by the delegate under section 52E (1) of the *Therapeutic Goods Act 1989* includes (c) the toxicity.

The decision to increase the Schedule 6 cut-off from 2 per cent to 4 per cent or less for abamectin for pesticidal use incorporated the following reasons:

- the toxicity of abamectin is well characterised and increasing the Schedule 6 cut-off from 2 per cent to 4 per cent retains an adequate margin of exposure for workers using this product.

**Schedule entry**

**Schedule 6 – Amendment**

ABAMECTIN – Amend entry to read:

ABAMECTIN:

(a) in preparations for pesticidal use containing 2.4 per cent or less of abamectin except when included in Schedule 5; or

(b) in slow-release plastic matrix ear tags for livestock use containing 1 g or less of abamectin.

### 1.2 CARBONYL SULFIDE

**Scheduling proposal**

The Chemicals Scheduling Delegate considered a proposal to create new Schedule 7 and Appendix J entries for carbonyl sulfide in the Standard for the Uniform Scheduling of Medicines and Poisons.

The delegate referred the proposal to the Advisory Committee on Chemicals Scheduling (ACCS) for advice.

**Scheduling history**

Carbonyl sulfide (COS) has not been considered previously.

**Scheduling status**

COS is not listed in the SUSMP.

**Public pre-meeting submissions**

No public submissions were received.
ACCS advice to the delegate

The ACCS recommended that carbonyl sulfide when packed and labelled for use as a fumigant be included in Schedule 7.

The matters under subsection 52E (1) of the *Therapeutic Goods Act 1989* considered relevant by the Committee included; (a) the risks and benefits of the use of a substance, (b) the purpose for which a substance is to be used and the extent of use of a substance, (c) toxicity and (d) the dosage, formulation, labelling, packaging and presentation of a substance.

The following reasons were noted:

- COS was efficient against stored grain pests and imported biological products. It would be an efficient substitute for other toxic fumigants.
- There was a risk of acute toxicity for applicators and bystanders.
- COS has a steep acute dose response curve and neurotoxicity.
- Toxicological database was limited.
- The toxicity profile of COS satisfies the criteria for Schedule 7.
- As a fumigant, it will require specialist training and equipment for use.

Delegate's consideration

The delegate considered the following in regards to this proposal:

- the evaluation report (not publically available);
- scheduling application;
- ACCS advice;
- section 52E of the *Therapeutic Goods Act 1989*;
- scheduling factors\(^2\); and
- other relevant information.

Delegate's interim decision

The delegate accepts the recommendation of the ACCS that carbonyl sulfide be listed in Schedule 7 and Appendix J.

The proposed implementation date for this decision is 1 September 2013.

The relevant matters considered by the delegate under section 52E (1) of the *Therapeutic Goods Act 1989* includes (a) the risks and benefits (b) the purpose, (c) the toxicity and (d) the dosage, formulation, labelling, packaging and presentation.

The decision to include carbonyl sulfide in Schedule 7 and Appendix J incorporated the following reasons:

---

• COS has the potential to cause neurotoxicity and must be carefully handled. However, the availability of an alternate fumigant to possibly replace other more toxic fumigants is a potential benefit.

• The acute toxicity of COS appears to fit with Schedule 6 criteria, but the steepness of the dose-response curve, the potential for neurotoxicity with chronic exposure, and the gaps in the available toxicity data suggest that Schedule 7 would be more appropriate.

• Workers using COS as a fumigant will need appropriate training and specialist equipment to mitigate exposure.

Schedule entry

SCHEDULE 7 – NEW ENTRY

CARBONYL SULFIDE when packed and labelled for use as a fumigant.

APPENDIX J PART 2– NEW ENTRY

<table>
<thead>
<tr>
<th>POISON</th>
<th>CONDITION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbonyl sulfide</td>
<td>1</td>
</tr>
</tbody>
</table>

[Secretariat note: Condition 1. Not to be available except to authorised or licensed persons.]

1.3 CHLORFENAPYR

Scheduling proposal

The Chemicals Scheduling Delegate considered a proposal to create a new Schedule 5 entry for preparations containing 0.5 per cent or less chlorfenapyr, with consequent amendments to the current Schedule 7 and Schedule 6 entries in the Standard for the Uniform Scheduling of Medicines and Poisons.

The delegate referred the proposal to the Advisory Committee on Chemicals Scheduling (ACCS) for advice.

Scheduling history

In February 1996, the NDPSC considered the scheduling of chlorfenapyr. The NDPSC noted that in the dog an approximate oral LD₅₀ of 9 mg/kg was determined when a single dose of 10 mg/kg resulted in the rapid death of 2 females. In chronic rat and dog dietary studies high doses were also reported to cause mild non-regenerative anaemia, which was unrelated to blood loss. A NOEL of 2.6 mg/kg/day in a rat dietary study was based on reduced weight gain and neurological lesions in male rats receiving higher doses. A NOEL of 2.1 mg/kg/day was determined in a 12 month dog study based on elevated creatinine levels in dogs receiving
higher doses. In a rat developmental study no significant abnormalities were seen at the highest dose of 225 mg/kg/day. Based on the toxicology profile of chlorfenapyr, the NDPSC decided to include it in Schedules 6 and 7.

Scheduling status

Preparations containing 36 per cent or less chlorfenapyr are listed in Schedules 6 and all other preparations are listed in Schedule 7.

ACCS advice to the delegate

The ACCS recommended that chlorfenapyr in preparations containing 0.5 per cent or less of chlorfenapyr be included in Schedule 5.

The matters under subsection 52E (1) of the Therapeutic Goods Act 1989 considered relevant by the Committee included; (a) the risks and benefits of the use of a substance, (b) the purpose for which a substance is to be used and the extent of use of a substance, (c) toxicity and (d) the dosage, formulation, labelling, packaging and presentation of a substance.

The following reasons were noted:

- chlorfenapyr is efficient against domestic and commercial insect and arachnid pests.
- risk arises from the mechanism of toxicity of the product and its LD$_{50}$.
- dosage and formulation fits the criteria for Schedule 5, i.e. available in a ready use pack and the risk is reduced by the packaging.

Delegate's consideration

The delegate considered the following in regards to this proposal:

- the evaluation report (not publically available);
- scheduling application;
- ACCS advice;
- section 52E of the Therapeutic Goods Act 1989;
- scheduling factors$^3$; and
- other relevant information.

Delegate's interim decision

The delegate accepts the advice of the ACCS and agrees that products containing 0.5 per cent or less meet criteria for listing in Schedule 5. Accordingly, the delegate proposes to create a new Schedule 5 entry for chlorfenapyr.

The proposed implementation date for this decision is 1 September 2013.

---


Delegates’ reasons for interim decision

May 2013
The relevant matters considered by the delegate under section 52E (1) of the *Therapeutic Goods Act 1989* includes (c) the toxicity and (d) the dosage, formulation, labelling, packaging and presentation.

The decision to include 0.5 per cent or less chlorfenapyr in Schedule 5 incorporated the following reasons:

- the toxicity of chlorfenapyr is well characterised and creating a new Schedule 5 entry for a product containing 0.5 per cent retains an adequate margin of exposure for workers using this product.
- the product under consideration is to be formulated in a ready-use pack, which is expected to minimise exposure potential for workers using the product.

**Schedule entry**

**SCHEDULE 5 – NEW ENTRY**

CHLORFENAPYR in preparations containing 0.5 per cent or less of chlorfenapyr.

**SCHEDULE 6 - AMENDMENT**

CHLORFENAPYR – Amend entry to read:

CHLORFENAPYR in preparations containing 36 per cent or less of chlorfenapyr except when included in Schedule 5.

**SCHEDULE 7 - AMENDMENT**

CHLORFENAPYR – Amend entry to read:

CHLORFENAPYR except when included in Schedules 5 or 6.

**1.4 EUBACTERIUM SP**

**Scheduling proposal**

The Chemicals Scheduling Delegate considered a proposal to create a new Schedule 5 entry for *Eubacterium* sp in the Standard for the Uniform Scheduling of Medicines and Poisons.

The delegate referred the proposal to the Advisory Committee on Chemicals Scheduling (ACCS) for advice.

**Scheduling history**

In February 2009, the NDPSC considered scheduling of *Eubacterium* sp. strain DSM 11798. The NDPSC noted that strain DSM 11798 had low acute dermal toxicity in rats, was not a skin or eye irritant in rabbits and was not a skin sensitiser in guinea pigs. The applicant also submitted a 90-day sub-chronic oral study in rats, but no acute oral study nor a scientific argument as to why one was not provided. The NDPSC noted that strain DSM 11798 showed no evidence of toxicity or adverse effects up to $4.52 \times 10^5$ CFU/kg bw/day, equivalent to 200 mg/kg bw/day, via repeated oral administration. The NOEL was therefore >
4.52 x 10^5 CFU/g or 200 mg/kg bw/day. The NDPSC noted that there were insufficient data provided on various toxicity studies and decided not to make a scheduling decision.

**Scheduling status**

_Eubacterium_ sp. is not specifically scheduled.

**Public pre-meeting submissions**

No public submissions were received.

**ACCS advice to the delegate**

The ACCS decided that it is unable to make a scheduling recommendation on _Eubacterium_ sp. or on strain DSM11798 on the basis of the insufficiency of the data provided.

The matters under subsection 52E (1) of the _Therapeutic Goods Act 1989_ considered relevant by the Committee included; (a) the risks and benefits of the use of a substance, (b) the purpose for which a substance is to be used and the extent of use of a substance, (c) the toxicity and (d) the dosage, formulation, labelling, packaging and presentation of a substance.

The reasons for the recommendation comprised the following:

- reduction of adverse effects of feed mycotoxins in intensive animal production.
- additive to feed of pigs and poultry to minimise the effects of feed mycotoxins. Potentially widespread use in animal industries.
- insufficient data on the specific characteristics of the organism to species level and quality assurance for the strain purity.
- in addition, requiring informed comment on substrate specificity.
- insufficient data on potential human pathogenicity and/or infectivity of the organism by all potential exposure routes, including intramuscular and intraperitoneal and intradermal.
- submitted data indicated low toxicity except for acute inhalation.
- presentation as a coarse particle feed premix.

**Delegate's consideration**

The delegate considered the following in regards to this proposal:

- the evaluation report (not publically available);
- scheduling application;
- ACCS advice;
- section 52E of the _Therapeutic Goods Act 1989_;
Delegates’ reasons for interim decision

May 2013

· scheduling factors; and
· other relevant information.

Delegate's interim decision

The delegate has decided to make a new entry for *Eubactrium* sp. strain DSM11798 in Appendix B.

The proposed implementation date for this decision is 1 September 2013.

The relevant matters considered by the delegate under section 52E (1) of the *Therapeutic Goods Act 1989* includes (a) the risks and benefits and (c) the toxicity.

The decision to include *Eubactrium* sp. strain DSM11798 in Appendix B incorporated the following reasons:

- this bacterial product has low toxicity and mild irritancy potential. The mild irritancy potential could be linked with physical abrasivity of formulation ingredients rather than the bacteria itself.
- the applicant had adequately determined the pathogenicity of the naturally-occurring bacterial strain, low pathogenicity could be inferred from the arguments presented (mainly around it being an obligate anaerobe). The lack of specific pathogenicity tests should not be a reason to further defer a scheduling decision.
- overall toxicity profile was consistent with several other bacterial substances currently listed in Appendix B, and accordingly the delegate decided to accept the recommendation of the evaluation report to make a new entry in Appendix B for *Eubactrium* sp. strain DSM11798.

Schedule entry

*Appendix B, PART 3 New entry*

<table>
<thead>
<tr>
<th>SUBSTANCE</th>
<th>DATE OF ENTRY</th>
<th>REASON FOR LISTING</th>
<th>AREA OF USE</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Eubacterium</em> sp. strain DSM11798</td>
<td>Sep 2013</td>
<td>a</td>
<td>2.4</td>
</tr>
</tbody>
</table>

**PART 1**

**REASONS FOR ENTRY**

a Low Toxicity

---


Delegates’ reasons for interim decision

May 2013
PART 2

AREA OF USE

2. Veterinary

2.4 Feed additive

1.5 PYROXASULFONE

Scheduling proposal

The Chemicals Scheduling Delegate considered a proposal to delete the current pyroxasulfone Schedule 7 entry and amend the current Schedule 6 entry to a simple entry with no exemptions in the Standard for the Uniform Scheduling of Medicines and Poisons.

The delegate referred the proposal to the Advisory Committee on Chemicals Scheduling (ACCS) for advice.

Scheduling history

In September 2011, the delegate decided to create new Schedules 6 and 7 entries for pyroxasulfone. This decision included a cut-off to Schedule 6 from Schedule 7 for water dispersible granule preparations when used as a pre-emergence herbicide.

The delegate made this decision following the recommendation from the ACCS. The ACCS noted that while there were minimal acute toxicity concerns, there were serious repeat dose concerns, noting effects on the cardiac muscle even in short term studies. In addition to the cardiac concerns, there were nerve tissue effects at quite low exposure levels, and developmental neurotoxicity in longer term study. The ACCS also noted that a high margin of exposure (MOE) had been determined by the evaluator. However, the ACCS felt that the severity of the endpoints was such that the ACCS could not ignore the possibility of exposure. The Committee generally agreed that Schedule 7 was appropriate for the pyroxasulfone parent entry.

The ACCS noted that the evaluator had asked for a cut-off to Schedule 6 for products containing 85 per cent or less pyroxasulfone for pre-emergence herbicidal use. The ACCS agreed that the percentage component was unnecessary, particularly as the toxicity difference between the high concentration cut-off and the 100 per cent substance was likely to be minimal.

The ACCS noted that the likely exposure to pyroxasulfone given the use pattern was dermal and via inhalation, and that repeat dermal exposure was the main concern. The ACCS noted that this concern was significant enough to not allow any cut-offs from a Schedule 7 parent entry. The ACCS contended, however, that this concern was sufficiently mitigated for water dispersible granule formulations, due to their lower absorption potential. The ACCS suggested that this presentation could be the basis for a cut-off to Schedule 6. The ACCS agreed, noting the high MOEs determined by the evaluator for the water dispersible formulations, its minimised exposure potential and the additional risk mitigation measures intended to be implemented by the regulator through labelling.

Delegates’ reasons for interim decision
May 2013
Scheduling status

Pyroxasulfone is listed in Schedules 6 and 7.

ACCS advice to the delegate

The ACCS recommended that pyroxasulfone be rescheduled from Schedule 7 to Schedule 6 with no cut-offs.

The ACCS recommended an implementation date of 1 September 2013.

The matters under subsection 52E (1) of the Therapeutic Goods Act 1989 considered relevant by the Committee included; (a) the risks and benefits of the use of a substance, (c) the toxicity of a substance, (d) the dosage, formulation, labelling, packaging and presentation of a substance and (f) any other matters that the Secretary considers necessary to protect public health.

The following reasons were noted:

- new data allowing more informed judgement showing that findings, whilst still treatment-related, were not toxicologically significant.
- pyroxasulfone is no longer considered to be a developmental neurotoxicant.
- it would be unlikely that there would be any variation in toxicity between 100% and 85 per cent.
- lack of data to determine a cut-off.

Delegate's consideration

The delegate considered the following in regards to this proposal:

- the evaluation report (not publically available);
- scheduling application;
- ACCS advice;
- section 52E of the Therapeutic Goods Act 1989;
- scheduling factors\(^5\); and
- other relevant information.

Delegate's interim decision

The delegate has decided to accept the advice of the ACCS and the scheduling recommendation of the evaluation report, and consolidate the scheduling of pyroxasulfone in Schedule 6, with no cut-off.

The proposed implementation date for this decision is 1 September 2013.


Delegates’ reasons for interim decision

May 2013
The relevant matters considered by the delegate under section 52E (1) of the *Therapeutic Goods Act 1989* includes (c) the toxicity and (d) the dosage, formulation, labelling, packaging and presentation.

The decision to include pyroxasulfone in Schedule 6, with no cut-off incorporated the following reasons:

- the primary reason for including pyroxasulfone in Schedule 7 when originally scheduled was concern over its developmental neurotoxicity potential. This concern has been ameliorated by the presentation of new data and argument relating to the signal toxic event in rat studies. While the human relevance of the renal papillary tumours seen in male rats is still not completely resolved, the delegate agrees with the ACCS that this finding does not warrant retaining pyroxasulfone in Schedule 7.
- the high concentration of pyroxasulfone in the product under consideration does not allow for differentiation of its toxicity from the technical grade active substance. Hence no cut-off to a lower schedule is proposed.

**Schedule entry**

**SCHEDULE 6 – AMENDMENT**

PYROXASULFONE – Amend entry to read:

PYROXASULFONE, in water dispersible granule preparations when for pre-emergence herbicide use.

**SCHEDULE 7 – AMENDMENT**

PYROXASULFONE – Delete entry

PYROXASULFONE except when included in Schedule 6.

1.6 **SULFOXAFLOR**

**Scheduling proposal**

The Chemicals Scheduling Delegate considered a proposal to create a new Schedules 6 and/or 5 entries for sulfoxaflor in the Standard for the Uniform Scheduling of Medicines and Poisons.

The delegate referred the proposal to the Advisory Committee on Chemicals Scheduling (ACCS) for advice.

**Scheduling history**

Sulfoxaflor was not considered for scheduling previously.

**Scheduling status**

Sulfoxaflor is not specifically scheduled.
Neonicotinoid insecticides such as, clothianidin, imidacloprid, thiamethoxam are listed in Schedules 5 and 6, and nitenpyram, thiacloprid, and acetamiprid are listed in Schedule 6.

**Public pre-meeting submissions**

No public submissions were received.

**ACCS advice to the delegate**

The ACCS recommended that sulfoxaflor be included in Schedule 6 with a cut-off to Schedule 5 for preparations containing less than 25 per cent of sulfoxaflor.

The ACCS recommended an implementation date of 1 September 2013.

The matters under subsection 52E (1) of the *Therapeutic Goods Act 1989* considered relevant by the Committee included; (a) the risks and benefits of the use of a substance, (b) the purpose, (c) the toxicity of a substance and (d) the dosage, formulation, labelling, packaging and presentation of a substance.

The following reasons were noted:

- efficient against damaging insect pests and many agricultural and horticultural crops.
- toxic effects to applicator therefore require PPEs and label warning statements.
- not for domestic use.
- moderate toxicity of the active ingredient and lower toxicity of the preparation containing 24 per cent sulfoxaflor.

**Delegate’s consideration**

The delegate considered the following in regards to this proposal:

- the evaluation report (not publically available);
- scheduling application;
- ACCS advice;
- section 52E of the *Therapeutic Goods Act 1989*;
- scheduling factors; and
- other relevant information.

**Delegate’s interim decision**

The delegate accepts the advice of the ACCS and agrees that sulfoxaflor meets criteria for listing in Schedule 6. The delegate also proposes to create a new Schedule 5 entry for products containing 25 per cent or less sulfoxaflor.

The proposed implementation date for this decision is 1 September 2013.

---

The relevant matters considered by the delegate under section 52E (1) of the *Therapeutic Goods Act 1989* includes (c) the toxicity and (d) the dosage, formulation, labelling, packaging and presentation.

The decision to include sulfoxaflor in Schedules 5 and 6 incorporated the following reasons:

- the acute and chronic toxicity profiles of sulfoxaflor are consistent with the criteria for Schedule 6. The delegate accepts ACCS advice that the human relevance of the observed hepatocellular adenomas and Leydig cell tumours in rats is adequately addressed by the MOA studies.

- the proposed product containing 24 per cent sulfoxaflor demonstrates an adequate margin of exposure (MOE) estimates for its use by workers when used with appropriate personal protective equipment (PPE). This, along with its reduced acute toxicity profile justifies inclusion of the product in a lower schedule (Schedule 5).

- the basic recommendation that sulfoxaflor be included in Schedule 6 with a cut-off to Schedule 5, has been adopted, but a minor change to the Schedule 5 wording is proposed for consistency with other SUSMP entries relating to cut-offs.

**SCHEDULE 5 – NEW ENTRY**

SULFOXAFLOR in preparations containing 25 per cent or less of sulfoxaflor.

**SCHEDULE 6 – NEW ENTRY**

SULFOXAFLOR **except** when included in Schedule 5.
2. March 2013 meeting of the joint Advisory Committee on Chemicals Scheduling (ACCS) and the Advisory Committee on Medicines Scheduling – ACCS & ACMS # 5

2.1 ADRENALINE, BUPIVACAINE AND LIGNOCAIN

Scheduling proposal

The chemicals scheduling delegate and the medicines scheduling delegate (the delegates) considered a proposal to reschedule a veterinary preparation containing adrenaline, bupivacaine and lignocaine from Schedule 4 to Schedule 6 in the Standard for the Uniform Scheduling of Medicines and Poisons.

The delegates referred the proposal to the Advisory Committee on Chemicals Scheduling (ACCS) and the Advisory Committee on Medicines Scheduling (ACMS) for advice.

Scheduling history

Adrenaline

In January 1955, the Poisons Schedules Committee (PSC) listed adrenaline in Schedules 2 and 3 for preparations of less than 1 per cent and in Schedule 4 for preparations containing more than 1 per cent.

In May 1956, the PSC decided that the Schedule 2 entry was deleted and the Schedule 3 entry refined to exempt concentrations of less than 0.01 per cent.

In August 1985, the PSC decided to amend the Schedule 3 and 4 entries for adrenaline to raise the exemption to preparations containing 0.02 per cent, stating that such a low level is not toxic and does not pose a health risk except in diabetics.

In February 1999, the National Drugs and Poisons Schedule Committee (NDPSC) recommended that New Zealand harmonise with the Australian adrenaline scheduling. New Zealand subsequently agreed to this recommendation.

In February 2010, the NDPSC considered an application to include adrenaline auto-injector in Appendix H entry. The NDPSC agreed that auto-injectors were included in Schedule 3 to facilitate emergency access for a specific group of people rather than the usual purpose of the majority of Schedule 3 listings i.e. to provide the community with access to a beneficial therapeutic option which requires professional advice but not a prescription. The NDPSC agreed that it was concerned that advertising could undermine this distinction. The NDPSC decided that the inclusion of adrenaline in Appendix H was inappropriate.

Bupivacaine

In 1983 August, the PSC decided to include bupivacaine in Schedule 4.

Lignocaine

In February 1998, the NDPSC considered a submission for rescheduling of dermal preparations containing 1 per cent or less of lignocaine in packs of 30 g or less, from
Schedule 2 to unscheduled. The NDPSC decided that based on the use pattern at that time, it did not wish to amend the scheduling of lignocaine.

In May 1998, following its reconsideration of the applicant’s comments, and subsequent examination of public comments, the NDPSC decided that it did not wish to change the decision of the February 1998 Meeting and that lignocaine would remain a scheduled substance.

In October 2008, the NDPSC considered a proposal to broaden the current Schedule 2 exemption for dermal use (less than or equal to 2 per cent) to also exempt use on gums.

At that time the NDPSC decided that the current Scheduling remained appropriate.

The Trans-Tasman Harmonisation Working Party recommended that 2 per cent lignocaine or less in dermal preparations should be exempted from scheduling. This recommendation was adopted at the February 2001 NDPSC Meeting.

**Scheduling status**

Adrenaline, bupivacaine and lignocaine are listed in Schedule 4. Adrenaline and lignocaine, apart from the listing in Schedule 4, are also listed in Schedules 3 and 2 respectively.

**Public pre-meeting submissions**

Five public submissions (including a late submission) were received.

Two submissions (both have identical contents) indicated that inclusion of these substances in Schedule 6 could potentially lead to an increase in adoption of the use of these substances for mulesing, ultimately leading to improve welfare outcomes for lambs undergoing mulesing. These two submissions supported the scheduling proposal to reschedule these substances.

One submission indicated that it supported the rescheduling of adrenaline and lignocaine. The submission did not provide comments on bupivacaine.

One submission indicated that rescheduling these substances would potentially leads to misuse, including for treating castration wounds and injuries, therefore did not support the delegates’ proposal.

One late public submission indicated that it did not oppose the delegates’ rescheduling proposal, provided it does not result in Tri-solfen no longer being available to woolgrowers for the purpose of alleviating the pain associated with the mulesing procedure and as long as the scheduling requirements ensure that the product continues to be used in the manner intended and described on the product label.


**ACCS & ACMS advice to the delegate**

The joint ACCS & ACMS Committee recommends that the current scheduling of adrenaline, bupivacaine and lignocaine remains appropriate.

The matters under subsection 52E (1) of the *Therapeutic Goods Act 1989* considered relevant by the Committee included; (a) the risks and benefits of the use of a substance, (c) the

Delegates’ reasons for interim decision

May 2013
toxicity of a substance and (d) the dosage, formulation, labelling, packaging and presentation of a substance.

The following reasons were noted:

- insufficient data available to demonstrate that a change in Schedule will result in wider appropriate usage versus wider inappropriate usage.
- as mulesing is a regulated process, there is no evidence that rescheduling would improve the extent of use.
- rescheduling would increase the risk of the product being inappropriately used.
- rescheduling would increase the likelihood of larger quantities being available which could lead to misuse.
- Delegate's consideration

The delegate considered the following in regards to this proposal:

- scheduling application;
- ACCS & ACMS advice;
- section 52E of the Therapeutic Goods Act 1989;
- scheduling factors; and
- other relevant information.

**Delegates’ interim decision**

The delegates considered, and accepted, the advice of the joint ACCS & ACMS, advising that the specific uses of the veterinary product for pain relief in the practice of ‘mulesing’ sheep require veterinary supervision, and that changes to the existing Schedule 4 entries of the three active ingredients are not warranted. Accordingly, no scheduling changes are proposed in making an interim decision.

The matters under subsection 52E (1) of the Therapeutic Goods Act 1989 considered relevant by the Committee included; (b) the purpose, (c) the toxicity of a substance, (d) the dosage, formulation, labelling, packaging and presentation of a substance (e) the potential for abuse and (f) any other matters.

The following reasons were noted:

- as mulesing is a regulated process, there is no evidence that rescheduling would improve the extent of use.
- the toxicity of the local anaesthetic ingredients and the relatively narrow window of effectiveness in pain relief associated with mulesing, warrant appropriate supervision of treatment by a veterinarian.

---

rescheduling to Schedule 6 could result in the product, currently available in 100 ml injection vials, being made available in much larger bulk containers, increasing the risk of inappropriate use.

rescheduling from Schedule 4 to Schedule 6 could increase the risk of the product being inappropriately used for purposes other than pair relief after mulesing.

a broadening of use in pain relief for the practice of mulesing is a desirable outcome, but this can be achieved within existing scheduling arrangements, especially via advertising, which would remain restricted to professional journals and related sources.

### 2.2 TYLOSIN

**Scheduling proposal**

The chemicals scheduling delegate and the medicines scheduling delegate (the delegates) considered a proposal to reschedule tylosin from Schedule 5 to Schedule 4 in the Standard for the Uniform Scheduling of Medicines and Poisons.

The delegates referred the proposal to the Advisory Committee on Chemicals Scheduling (ACCS) and the Advisory Committee on Medicines Scheduling (ACMS) for advice.

**Scheduling history**

In November 1968, the then Poisons Schedule Sub-Committee (PSSC) recommended that an entry group ‘antibiotics’ be included in Schedule 4 except when tylosin and other macrolides bacitracin, erythromycin and oleandomycin when added to animal feedstuffs for the purpose of growth promotion in concentrations not exceeding 50 ppm, which should be exempt from scheduling. Antibiotic premixes for growth promotion purposes containing the antibiotics above in concentrations greater than 50 ppm but not in excess of 20,000 ppm should be exempt from Schedule 4 when packed and labelled in accordance with Schedule 6 of the Uniform Poisons Schedules. Water soluble antibiotic preparations intended for addition to animals' drinking water should not be made available without prescription.

In May 1977, the then Poisons Schedule Committee (PSC) decided to amend the Schedule 4 entry for antibiotics to include animal feedstuffs containing bacitracin, erythromycin, oleandomycin, tylosin and virginiamycin in concentration of 50 ppm or less of the total active antibiotic principles. The PSC was of the opinion that the continued use of antibiotics as growth promotions in animal feedstuffs could lead to an impairment of their efficacy in the treatment of human disease.

In May 1978 specific entries for antibiotics including tylosin, bacitracin, erythromycin, oleandomycin and virginiamycin were included in Schedule 4, except in animal feedstuffs for growth promotion in concentrations of 50 mg / kg or less of the total active antibiotic principle (remained Schedule 6).

In November 1986, the then Drugs and Poisons Schedule Standing Committee (DPSSC) considered a submission to remove tylosin from Schedule 4 to Schedule 6. The review noted that if the concentration of tylosin in the premix was increased it would increase the chance of erythromycin resistance occurring in possible human pathogens. The DPSSC decided not to remove the Schedule 4 entry and recommended the Schedule 6 level of tylosin in premixes be increased from 2 to 5 per cent.
In November 1990, the DPSC considered an apparent anomaly in the scheduling of tylosin. The DPSC confirmed the current scheduling that the Schedule 4 entry related to uses involving therapeutic claims while Schedule 6 entry was solely for growth promotion purposes.

In May 1993, the DPSC decided to include safety directions for a Schedule 6 tylosin stockfeed premix.

In February 1996, the National Drugs and Poisons Schedule Committee (NDPSC) decided to reschedule tylosin from Schedule 6 to Schedule 5. The NDPSC considered that the registered products for oral use fell within the acute oral criteria of the new draft guidelines for Schedule 5 and recommended that tylosin when in veterinary products for oral use should be classified as Schedule 5.

In 1999, the Joint Expert Technical Advisory Committee on Antibiotic Resistance (JETACAR) recommended “that all antibiotics for use in humans and animals (including fish) be classified as Schedule 4 (prescription only).” The JETACAR report also recommended that a review of the macrolides (tylosin, kitasamycin, oleandomycin) be undertaken as a priority to assess efficacy and to ensure that continued use is “not likely to impair the efficacy of any other prescribed therapeutic antibiotic or antibiotics for animal or human infections through the development of resistant strains of organisms.”

In February 2003, the NDPSC scheduled / rescheduled all antibiotics (except tylosin, kitasamycin, oleandomycin) for use in human and animals in Schedule 4: virginiamycin, bacitracin, cuprimyxin, erythromycin, hygromycin, nalidixic acid, nisin, spiramycin and avoparcin as part of its response to the recommendations (in 1999) of the JETACAR.

The October 2003 NDPSC meeting considered a letter sent to feed mill sales representatives from XXXXX in which the company highlighted the Committee’s decision regarding the rescheduling of virginiamycin to Schedule 4. XXXXX letter mentioned that XXXXX (containing tylosin) remained in Schedule 5 and was unaffected by the NDPSC decision. The NDPSC agreed to refer claims of inappropriate promotion of antibiotics that are yet to be reviewed under JETACAR to Expert Advisory Group on Antimicrobial Resistance (EAGAR) and the APVMA.

In June 2012, the joint Committee considered a referral from the medicines and chemicals scheduling delegates to consolidate the scheduling of all uses of tylosin in Schedule 4. The joint Committee agreed that they were unable to provide the scheduling delegates informed advice at that stage. The delegates noted that the APVMA review on macrolides was yet to be completed. The delegates therefore decided not to make a scheduling decision on this issue and referred this matter to the March 2013 joint Committee meeting for advice.

**Scheduling status**

Tylosin is listed in Schedules 4 and 5.

Tylosin is a macrolide antimicrobial agent approved in Australia by the APVMA for use in poultry, pigs and cattle. Currently (as of March 2013) tylosin is available as an injection, water-soluble antimicrobial preparation and as premix. While injectable and water-soluble formulations are in Schedule 4 (Prescription Animal Remedy), the feed premix formulations are, according to the concentration of tylosin in the marketed premix, either in Schedule 4 or in Schedule 5 (available over-the-counter without a prescription).
Public pre-meeting submissions

Five public submissions were received.

Two submissions supported the delegates’ proposal to reschedule tylosin from Schedule 5 to Schedule 4.

One submission requested that if tylosin is included in Schedule 4, implementation time be extended to deplete the products containing tylosin currently available on the market.

One submission indicated that if tylosin is included in Schedule 4, other antibiotics with greater risk profiles for antimicrobial resistance would need to be used. The Schedule 4 listing of tylosin would also increase the cost due to the requirement of a veterinarian consultation.

One submission suggested that the delegates continue to defer the tylosin rescheduling decision until various issues, including the senate review, are resolved.


ACCS and ACMS advice to the delegate

The ACCS & ACMS joint meeting advises the delegates that it was unable to make a scheduling recommendation or to provide advice at this time due to lack of provision to the Committees of all of the available data in the form of the macrolide review or an alternative acceptable process.

Delegate's consideration

The delegate considered the following in regards to this proposal:

- the evaluation report (not publically available);
- scheduling application;
- ACCS & ACMS advice;
- section 52E of the Therapeutic Goods Act 1989;
- scheduling factors; and
- other relevant information.

Delegates’ interim decision

The delegates have decided to defer making an interim decision on the consolidation of the scheduling of tylosin into Schedule 4, pending receipt of further advice on the key issue of the risk of expanding antibiotic resistance associated with its use as an animal health feed additive (the current Schedule 5 and exempt uses).

---


Delegates’ reasons for interim decision
May 2013
The delegates have noted the further inability of the March 2013 joint ACCS & ACMS to offer definitive advice on this re-scheduling matter, since not all of the available data has been presented for review.

The delegates propose to seek further technical comment from a product sponsor in relation to this matter, and will then refer the matter back to the joint ACCS & ACMS advice on any necessary schedule changes.

2.3 TERMINOLOGY

Scheduling proposal

The chemicals scheduling delegate and the medicines scheduling delegate (the delegates) considered a proposal to include terms, such as synthetic, analogue and derivative, to the Part 1, Introduction in order to better define these terms, their intent and purpose in the SUSMP.

The delegates referred the proposal to the joint ACCS & ACMS for advice.

Scheduling history of synthetic cannabinoids

In July 2011, the Medicines Scheduling Delegate decided to include eight specific synthetic cannabis-like substances in Schedule 9.

In February 2012, the Medicines Scheduling Delegate decided to include another nine specific synthetic cannabis-like substances in Schedule 9.

Scheduling status of synthetic cannabinoids

There are several synthetic cannabinoids currently specifically listed in Schedule 4 (e.g. rimonabant), Schedule 8 (e.g. nabilone) and Schedule 9 (e.g. JWH-018). These entries also capture a number of other synthetic cannabinoids as derivatives in accordance with Part 1 (2) of the SUSMP.

Public pre-meeting submissions

Three public submissions were received.

A submission indicated that the current understanding of "analogue" and "derivative" encompasses "ethers, esters, and salts" and indicated that this definition may be too broad. The submission suggested that stereoisomers and salts exhibiting no substantially different pharmacological properties (both pharmacokinetic and pharmacodynamic) from the parent molecule should be considered analogues or derivatives. The submission asserted that any broadening of this definition seems to run aground against intellectual patent law.

Two submissions indicated that the recent Drug Analogue workshop proposed that a new definition of a drug analogue should replace the existing definition in the Commonwealth Criminal Code Act 1995. One of the submission noted that it was intended that this new drug analogue definition should be used in its entirety either by inclusion into or by reference from the various Australian jurisdiction drug or poisons Acts. One of these submission also suggested that the current use of the term derivative in the context of the SUSMP includes a balanced consideration of the toxicology and pharmacology of a new drug, in addition to the...
chemical structure. The submission suggested that any adoption of a uniform analogue definition would potentially need to be complemented by a similar consideration of the toxicology and pharmacology aspects of new drugs.


**ACCS and ACMS advice to the delegate**

The joint ACCS & ACMS Committee does not support the inclusion of the terms ‘analogue’, ‘derivative’ and ‘synthetic’ in Part 1, Interpretation, of the SUSMP.

**Delegate's consideration**

The delegate considered the following in regards to this proposal:

- scheduling application;
- ACCS & ACMS advice;
- section 52E of the *Therapeutic Goods Act 1989*;
- scheduling factors\(^9\); and
- other relevant information.

**Delegates’ interim decision**

The delegates considered the advice of the joint meeting of the ACCS & ACMS, advising that there is no support for including the terms ‘analogue’, ‘derivative’ and ‘synthetic’ in Part 1, Interpretation, of the SUSMP. The delegates noted from the discussion, that jurisdictions have been adequately served by the existing entries in Part 1. They have been able to effectively manage control over substances listed in Schedule 9, including the primary issue raised in the submission relating to interpretations involved in prosecutions. Therefore, the delegates determined that the requested changes (or clarifications) to definitions in Part 1 of the SUMSP are not warranted.

---


**Delegates’ reasons for interim decision**

May 2013
3. March 2013 meeting of the Advisory Committee on Medicines Scheduling – ACMS # 8

3.1 BENZODIAZEPINES

Scheduling proposal

The medicines scheduling delegate considered a proposal to reschedule benzodiazepines from Schedule 4 to Schedule 8 in the Standard for the Uniform Scheduling of Medicines and Poisons.

The delegate referred the proposal to the Advisory Committee on Medicines Scheduling (ACMS) for advice.

Scheduling history

In May 1982, the general class of benzodiazepines was included into Schedule 4. In May 1986, individual benzodiazepine substances were listed in Schedule 4 (bromazepam, diazepam).

A review of scheduling for the benzodiazepine class of drugs in August 1998 found that the benzodiazepines entries in Schedule 4 remained appropriate, with the exception of the substance flunitrazepam, which was included in Schedule 8 in November 1997 based on public health concerns associated with abuse of this substance.

The rescheduling of Alprazolam as a Schedule 8 substance was considered by the National Drugs and Poisons Scheduling Committee in June 2010, after the up-scheduling of Flunitrazepam. The committee stated that there was insufficient evidence to support a Schedule 8 restriction for alprazolam and agreed that until such information is provided to support a rescheduling application, the Schedule 4 entry remained appropriate.

Scheduling status

Group listing of benzodiazepine derivatives is included in Schedule 4. Other specific benzodiazepines are also included in Schedule 4 (other than flunitrazepam) and in Appendix K.

Public pre-meeting submissions

Seventy public pre-meeting submissions were received.

Fifty-two of those submissions were against the rescheduling of benzodiazepines on the grounds of negative impact to business. The main impacts related to increased administrative burden and the need to increase security for those who administer or dispense benzodiazepines, such as aged care facilities and pharmacies.

Sixteen submissions were in support of rescheduling benzodiazepines in Schedule 8 citing public health concerns associated with the abuse and trafficking of these substances.

Two submissions did not provide comment either for or against. One noted the misuse of alprazolam; the other outlined business impacts should the proposal go ahead.
At least 12 submissions—both for and against—suggested that alprazolam be included under Schedule 8 due to concerns regarding abuse of this substance.


ACMS advice to the delegate

The ACMS recommended that alprazolam be rescheduled from Schedule 4 to Schedule 8 and that the scheduling of the remaining benzodiazepines remains appropriate. The ACMS also recommends that benzodiazepines be included in Appendix D, paragraph 5.

The matters under subsection 52E (1) of the Therapeutic Goods Act 1989 considered relevant by the Committee included; (a) the risks and benefits of the use of a substance, (b) the purposes for which a substance is to be used and the extent of use of a substance, (c) the toxicity of a substance, (d) the dosage, formulation, labelling, packaging and presentation of a substance and (e) the potential for abuse of a substance.

The reasons for the recommendation comprised the following:

- alprazolam: a public health problem of widespread use with possible increased toxicity. It does not appear to have any additional therapeutic benefits compared with any other substance in the class.
- alprazolam: listing in Schedule 8 does not restrict short-term use for the approved indication. There has also been a rapid increase in use compared with other benzodiazepines.
- alprazolam: increased morbidity and mortality in overdose. Misuse, particularly in association with opioids.
- alprazolam: evidence of widespread misuse.

Delegates consideration

The delegate considered the following in regards to this proposal:

- scheduling proposal;
- public submissions received;
- the evaluation report (not publicly available);
- ACMS advice;
- section 52E of the Therapeutic Goods Act 1989;
- scheduling factors\(^{10}\);
- other relevant information.

---


Delegates’ reasons for interim decision
May 2013
Delegates interim decision

The delegate has made the following interim decisions:

- That alprazolam be rescheduled from Schedule 4 to Schedule 8;
- That the scheduling of the remaining benzodiazepines remains appropriate; and
- That benzodiazepines be included in Appendix D, paragraph 5.

The proposed implementation date for this decision is 1 January 2014.

The delegate decided that the relevant matters under section 52E (1) of the *Therapeutic Goods Act 1989* include (a) the risks and benefits of the use of a substance, (b) the purposes for which a substance is to be used and the extent of use of a substance, (c) the toxicity of a substance, (d) the dosage, formulation, labelling, packaging and presentation of a substance and (e) the potential for abuse of a substance.

The reasons for the interim decision comprised the following:

- Alprazolam has increased morbidity and mortality in overdose with possible increased toxicity. It does not appear to have any additional therapeutic benefits compared with any other substance in the class.
- There has also been a rapid increase in use of Alprazolam compared with other benzodiazepines and evidence of widespread misuse.
- Alprazolam - Concerns of possible increased toxicity.
- Alprazolam - concern that current pack size is inappropriate for indications.
- There is evidence of abuse of the substance and misuse with opioids.
- Listing in Schedule 8 of Alprazolam does not restrict its short-term use for the approved indication.

Scheduling entry

*SCHEDULE 4 – AMENDMENT*

ALPRAZOLAM – Delete entry.

*SCHEDULE 8 – NEW ENTRY*

ALPRAZOLAM.

*APPENDIX D, PARAGRAPH 5 – NEW ENTRY*

BENZODIAZEPINE DERIVATIVES, including those separately specified in Schedule 4 and Schedule 8.

Benzodiazepine entries will be amended to include the “#” symbol beside their name to indicate their inclusion under Appendix D, paragraph 5.
3.2 DICLOFENAC

Scheduling proposal

The medicines scheduling delegate considered a proposal to exempt from scheduling diclofenac, when presented as a 140 mg or less diclofenac transdermal drug delivery system from the Standard for the Uniform Scheduling of Medicines and Poisons.

The delegate referred the proposal to the Advisory Committee on Medicines Scheduling (ACMS) for advice.

Scheduling history

In March 1981, diclofenac was included in Schedule 4.

In February 1997, the National Drugs and Poisons Schedule Committee (NDPSC) rescheduled from Schedule 4 to Schedule 2, dermal preparations (creams) containing 1 per cent or less of diclofenac. This decision was based on the safety profile of a 1 per cent formulation and the then approved indications for use in readily recognised conditions (minor pain relief), which did not include treatment of solar keratosis.

In August 1999, the NDPSC decided that the scheduling of diclofenac in dermal preparations remained appropriate after considering recommendations from the Trans-Tasman Harmonisation Working Party to exempt diclofenac for dermal use.

In November 1999, the NDPSC deferred consideration of the scheduling of diclofenac in dermal preparations.

In February 2000, the NDPSC exempted dermal preparations of diclofenac from scheduling based on additional safety data.

In March 2011, following advice from the December 2010 ACMS meeting, the delegate included dermal preparations containing more than 1 per cent of diclofenac or preparations for the treatment of solar keratosis in Schedule 4.

In February 2012, following advice from the October 2011 ACMS meeting, the delegate rescheduled dermal preparations containing more than 1 per cent up to 4 per cent or less of diclofenac, except when for the treatment of solar keratosis, to Schedule 2. The delegate also confirmed that Schedule 4 remained appropriate for preparations containing more than 4 per cent of diclofenac, that preparations containing 1 per cent or less of diclofenac would remain unscheduled and that preparations for use in solar keratosis would remain in Schedule 4.

In February 2013, following advice from the October 2012 ACMS meeting, the delegate included transdermal preparations for topical use containing 140 mg or less of diclofenac in Schedule 2, with an implementation date of 1 May 2013.

Scheduling status

Diclofenac is currently included in Schedules 2, 3 and 4 and Appendices F and H.

Public pre-meeting submissions

Four public pre-meeting submissions were received.
Three did not support the proposal.

One indicated that it would have liked to comment on the proposed scheduling changes but felt that there was not information available regarding the proposal in order to comment.


**ACMS advice to the delegate**

The ACMS recommended that the current scheduling of diclofenac remains appropriate.

The matter under subsection 52E (1) of the Therapeutic Goods Act 1989 considered relevant by the ACMS included (d) dosage, formulation, labelling, packaging & presentation.

The recommendation comprised of the following:

- there has been no clinical/marketing experience with this novel formulation in Australia; and
- Schedule 2 allows capacity to obtain professional advice from a pharmacist at the time of purchase.

**Delegates consideration**

The delegate considered the following in regards to this proposal:

- scheduling proposal;
- public submissions received;
- the evaluation report (not publicly available);
- ACMS advice;
- section 52E of the Therapeutic Goods Act 1989;
- scheduling factors\(^{11}\);
- other relevant information.

**Delegates interim decision**

The delegate has made an interim decision that the current scheduling of diclofenac remains appropriate.

The delegate decided that the relevant matters under section 52E (1) of the Therapeutic Goods Act 1989 include (d) the dosage, formulation, labelling, packaging and presentation of a substance.

The decision that the entry for diclofenac remains appropriate included the following reasons:

- there has been no clinical/marketing experience with this novel formulation in Australia; and

---


Delegates’ reasons for interim decision
May 2013
• Schedule 2 allows capacity to obtain professional advice from a pharmacist at the time of purchase.

3.3 HYDROCORTISONE AND HYDROCORTISONE ACETATE

Scheduling proposal

The medicines scheduling delegate considered a proposal to reschedule preparations containing 1 per cent or less of hydrocortisone and hydrocortisone acetate when combined with anti fungal substances for dermal use from Schedule 3 to Schedule 2 in the Standard for the Uniform Scheduling of Medicines and Poisons.

The delegate referred the proposal to the Advisory Committee on Medicines Scheduling (ACMS) for advice.

Scheduling history

In May 1981, the Poisons Schedule Committee (PSC) confirmed that the scheduling of hydrocortisone remained appropriate, i.e. in Schedule 4. The PSC confirmed this position again in February 1982.

In August 1985, the PSC decided to reschedule to Schedule 3, 0.5% or less of hydrocortisone when present as the only therapeutically active substance.

In November 1988, the Drugs and Poisons Schedule Committee (DPSC) decided not to reschedule 1% or less of hydrocortisone to Schedule 3 on the basis of advice from the then Australian Drug Evaluation Committee (ADEC) that the product in question was pharmacologically more active than other brands of 1% hydrocortisone cream in causing vasoconstriction.

In May 1995, the National Drugs and Poisons Schedule Committee (NDPSC) considered an application to reschedule rectal preparations containing hydrocortisone and cinchocaine from Schedule 4 to Schedule 3. The NDPSC gave in-principle support to the scheduling proposal, pending further advice. A decision was subsequently made out-of-session to reschedule hydrocortisone and cinchocaine topical preparations for rectal use, from Schedule 4 to Schedule 3.

In February 1996, the NDPSC confirmed that the intent of the May 1995 decision was to allow preparations containing 0.5% or less of hydrocortisone (alone or in combination with cinchocaine) to be available for rectal use (internal and externally) in both the ointment and suppository form, as Schedule 3.

In August 1998, the NDPSC decided not to list hydrocortisone and cinchocaine rectal preparations in Appendix H. This decision was primarily on the grounds that the incidence of misdiagnosis of fungal infections may be increased.

In February 1999, the NDPSC decided to reschedule hydrocortisone and hydrocortisone acetate (for dermal use containing 0.5% or less of hydrocortisone in packs containing 30 g or less of such preparation, with no other therapeutically active substance or an antifungal as the only other therapeutically active substance), to Schedule 2. The Schedule 3 entry was also amended to include a specific reference to suppositories.
In May 1999, the NDPSC decided to include hydrocortisone in preparations for rectal use in Appendix H. This decision was based on controls on advertising and that the Therapeutic Good Advertising Council allows advertising of haemorrhoid treatments, provided there are statements limiting the nature of the relief; that advertising of both Schedule 2 and Schedule 3 products will enable pharmacists to offer comparative professional advice; and the issue of possible systemic absorption would be addressed through pharmacist counselling.

In November 2001, the NDPSC considered the scheduling of products containing hydrocortisone and hydrocortisone acetate, with astringents as active ingredients, for rectal use. The NDPSC decided to amend the scheduling of hydrocortisone and hydrocortisone acetate to exempt unscheduled astringents and restore the product to Schedule 3. The NDPSC considered that the presence of aluminium acetate and zinc oxide the product, whilst therapeutically active, were there primarily for their astringent effects rather than for systemic effects.

In June 2002 the NDPSC decided not to include hydrocortisone for dermal use in Appendix H. However, in response to post-meeting comment, the October 2002 NDPSC reconsidered this scheduling proposal and decided to include hydrocortisone for dermal use in Appendix H.

In October 2005, the NDPSC considered an application for the rescheduling of hydrocortisone acetate (in combination with an anaesthetic) for rectal use from Schedule 3 to Schedule 2. The NDPSC decided that the scheduling of hydrocortisone remained appropriate. This decision was based on concerns that consumers may sometimes have difficulty in differentiating between haemorrhoids and other conditions for which the use of a corticosteroid would be inappropriate; that if used on infected skin, there was potential for any infection to be masked or exacerbated; and concern that the safety data presented as part of the rescheduling application did not truly reflect the safety of the product for anorectal use as it included all adverse events relating to hydrocortisone, regardless of route, dose or duration of treatment.

In June 2006, the NDPSC reconsidered an application to reschedule hydrocortisone acetate (in combination with an anaesthetic) for rectal use. After due consideration of the new safety data presented, the NDPSC decided that the current scheduling of hydrocortisone and hydrocortisone acetate remained appropriate. The applicant had again not adequately justified exactly what advantage there would be to the consumer, should this product be down scheduled and therefore accessed without mandatory intervention of the pharmacist.

In February 2007, the NDPSC decided to reschedule hydrocortisone 0.5% in combination with an anaesthetic for rectal use from Schedule 3 to Schedule 2 to harmonise with New Zealand.

In June 2007, the NDPSC decided to amend the Schedule 2 and 3 entries to only capture human use. This was a result of a decision to vary the February 2007 decision to capture all veterinary use in Schedule 4.

In October 2007, the NDPSC decided to correct the wording of the Schedule 2 entry for hydrocortisone to specify human rectal use, in line with the decision of the June 2007 NDPSC meeting.
In June 2008, the NDPSC decided to include hydrocortisone in Appendix F, Part 3, with warning statements 38, 72, 73, 74 and 75 (for dermal use when included in Schedule 2 or 3), and warning statements 38 & 75 (for topical rectal use when included in Schedule 2 or 3).

**Scheduling status**

Hydrocortisone is currently included in Schedules 2, 3 and 4 and Appendices F and H. Hydrocortisone acetate is included in Schedules 2 and 3.

**Public pre-meeting submissions**

Four public pre-meeting submissions were received. One supported the scheduling proposal. Three did not support the scheduling proposal.


**ACMS advice to the delegate**

The ACMS recommended that the current scheduling of hydrocortisone and hydrocortisone acetate remains appropriate.

The matters under subsection 52E (1) of the *Therapeutic Goods Act 1989* considered relevant by the ACMS include (a) the risks and benefits of the use of a substance.

The reason for the recommendation comprised of the following:

- This product contains an increased concentration of hydrocortisone. Therefore, there are increased risks of:
  - masking symptoms, particularly in children, which can be mitigated by mandatory pharmacist intervention;
  - exacerbation of bacterial infections through inappropriate application;
  - inappropriate use with a higher concentration, with no demonstrated increase in benefit were it to be down-scheduled.

**Delegates consideration**

The delegate considered the following in regards to this proposal:

- scheduling proposal;
- public submissions received;
- the evaluation report (not publicly available);
- ACMS advice;
- section 52E of the *Therapeutic Goods Act 1989*;
- scheduling factors;\(^{12}\)
- other relevant information.


Delegates’ reasons for interim decision
May 2013
Delegates’ interim decision

The delegate has made an interim decision that the current scheduling of hydrocortisone and hydrocortisone acetate remains appropriate.

The delegate decided that the relevant matters under section 52E (1) of the *Therapeutic Goods Act 1989* include (a) the risks and benefits of a substance.

The decision that the entry for hydrocortisone and hydrocortisone acetate remains appropriate included the following reasons:

- This product contains an increased concentration of hydrocortisone. Therefore, there are increased risks of:
  - masking symptoms, particularly in children, which can be mitigated by mandatory pharmacist intervention;
  - exacerbation of bacterial infections through inappropriate application;
  - inappropriate use with a higher concentration, with no demonstrated increase in benefit were it to be down-scheduled.

### 3.4 LISDEXAMFETAMINE

#### Scheduling proposal

The medicines scheduling delegate considered a proposal to include lisdexamfetamine in Schedule 8 in the Standard for the Uniform Scheduling of Medicines and Poisons.

The delegate referred the proposal to the Advisory Committee on Medicines Scheduling (ACMS) for advice.

#### Scheduling history

There is no scheduling history for lisdexamfetamine as is it not currently scheduled.

#### Scheduling status

Lisdexamfetamine is not scheduled.

#### Public pre-meeting submissions

One public pre-meeting submission was received, who supported the proposal.


#### ACMS advice to the delegate

The ACMS recommended that lisdexamfetamine be listed under Schedule 8.

The matters under subsection 52E(1) of the *Therapeutic Goods Act 1989* considered relevant by the ACMS include: (a) the risks and benefits of the use of a substance, and (e) the potential for abuse.
The reasons for the recommendation comprised of the following:

- On account of its long acting characteristics, it is useful and convenient for the treatment of ADHD, but it does carry all the risks of the amphetamines.
- Amphetamines are well established as substances of abuse which warrant inclusion in Schedule 8.

Delegates consideration

The delegate considered the following in regards to this proposal:

- scheduling proposal;
- public submissions received;
- ACMS advice;
- section 52E of the *Therapeutic Goods Act 1989*;
- scheduling factors\(^\text{13}\);
- other relevant information.

Delegates interim decision

The delegate has made an interim decision that lisdexamfetamine be listed under Schedule 8.

The proposed implementation date for this decision is 1 September 2013.

The delegate decided that the relevant matters under section 52E (1) of the *Therapeutic Goods Act 1989* include (a) the risks and benefits of a substance and (e) the potential for abuse of a substance.

The decision that the entry for including lisdexamfetamine in Schedule 8 included the following reasons:

- On account of its long acting characteristics, it is useful and convenient for the treatment of ADHD, but it does carry all the risks of the amphetamines.
- Amphetamines are well established as substances of abuse which warrant inclusion in Schedule 8.

Scheduling entry

*SCHEDULE 8 – NEW ENTRY*

LISDEXAMFETAMINE.

3.5 NABIXIMOLS

Scheduling proposal

The medicines scheduling delegate considered a proposal to reschedule Nabiximols from Paragraph 3 of Appendix D to Paragraph 1 of Appendix D in the Standard for the Uniform Scheduling of Medicines and Poisons.

The delegate referred the proposal to the Advisory Committee on Medicines Scheduling (ACMS) for advice.

Scheduling history

In October 2009, the committee considered an entry specific for Cannabis sativa extract, Nabiximols, after the issue that certain jurisdictions were unable to allow SAS access to the substance as it was captured under Schedule 9 was raised in the June 2009 meeting. As discussed in June, the Committee members agreed on the Schedule 8 listing. The Committee also agreed that the Schedule 8 entry should limit the allowed presentation to buccal sprays as this would further reinforce the very restricted scope of this entry and would require any new presentation to be brought to the attention of the Committee.

In May 2010, Nabiximols were included in Schedule 8 and Appendices D and K.

The committee advised that Nabiximols needed to be added to Appendix D, paragraph 3 to limit access through SAS Category A. This addition would allow restricted access to Nabiximols only, not to cannabis extracts but would not prohibit use for clinical trials provided by an authorised prescriber only. The Committee agreed to not restrict the Schedule 8 Nabiximols entry by indication (for Multiple Sclerosis).

Members additionally agreed that it would be appropriate to include Nabiximols in Appendix K due to sedating effects.

Scheduling status

Nabiximols are included in Schedule 8, Appendix D and Appendix K.

Nabiximols is defined with the Standard for the Uniform Scheduling of Medicines and Poisons as “botanical extract of Cannabis sativa, which includes the following cannabinoids: tetrahydrocannabinol, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acid, tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinol and cannabidiol (in approximately equal proportions) comprise not less than 90 per cent of the total cannabinoid content) in a buccal spray for human therapeutic use”.

Public pre-meeting submissions

Eight public pre-meeting submissions were received addressing the proposal to reschedule Nabiximols from Paragraph 3 of Appendix D to Paragraph 1 of the same appendix. All 8 submissions supported the proposal.


Delegates’ reasons for interim decision
May 2013
ACMS advice to the delegate

The ACMS recommended that paragraph 1 of Appendix D be amended to include the entry of Nabiximols.

The proposed implementation date for this decision is 1 September 2013.

The matters under subsection 52E(1) of the Therapeutic Goods Act 1989 considered relevant by the Committee included (a) the risks and benefits of the use of a substance.

The reasons for the recommendation comprised of the following:

Specialist oversight is required for safe prescribing of the drug and an entry in Appendix D paragraph 1 is consistent with TGA’s decision with respect to specialist prescribers for the current registered products.

Delegates consideration

The delegate considered the following in regards to this proposal:

- scheduling proposal;
- public submissions received;
- ACMS advice;
- section 52E of the Therapeutic Goods Act 1989;
- scheduling factors\(^{14}\);
- other relevant information.

Delegates interim decision

The delegate has made an interim decision to reschedule Nabiximols from Paragraph 3 of Appendix D to Paragraph 1 of Appendix D.

The delegate decided that the relevant matters under section 52E (1) of the Therapeutic Goods Act 1989 include (a) the risks and benefits of a substance.

The decision that the Appendix D entry for nabiximols be amended included the following reasons:

- Appendix D, paragraph 1, is for medicines approved on the ARTG for use in Australia whereas Appendix D, paragraph 3, is for medicines that are not included in the ARTG and thus not approved for use in Australia.
- One product containing nabiximols has been approved for use in Australia and is included on the ARTG.
- Specialist oversight is required for safe prescribing of the drug and an entry in Appendix D paragraph 1 is consistent with TGA’s decision with respect to specialist prescribers for the current registered products.

3.6 Oseltamivir

Scheduling proposal

The medicines scheduling delegate considered a proposal to reschedule oseltamivir for the treatment and prevention of influenza type A and type B from Schedule 4 to Schedule 3 in the Standard for the Uniform Scheduling of Medicines and Poisons.

The delegate referred the proposal to the Advisory Committee on Medicines Scheduling (ACMS) for advice.

Scheduling history

In November 2000, the National Drugs and Poisons Schedule Committee (NDPSC) decided to include oseltamivir in Schedule 4 following a recommendation made by the then Australian Drug Evaluation Committee (ADEC) to register a new drug application for Tamiflu® capsules, containing 75 mg of oseltamivir phosphate, for the treatment of infections due to influenza A and B viruses in adults and children aged twelve years and older.

In October 2004, the NDPSC considered an application to reschedule oseltamivir from Schedule 4 to Schedule 3, and for inclusion in Appendix H. The NDPSC deferred making a decision to allow input by the National Influenza Pandemic Action Committee (NIPAC). The NDPSC considered the available data to be inadequate in providing a reassurance that widening the availability of oseltamivir for the treatment of influenza through inclusion in Schedule 3 would not facilitate the spread of resistance to neuraminidase inhibitor (NI) class of drugs. The NDPSC also considered it important to its consideration if advice was received from authorities that deal with communicable diseases to gain an understanding of the implications a Schedule 3 availability of oseltamivir for the treatment of influenza would have on the national strategies for managing influenza epidemics or pandemics.

In October 2005, following receipt of advice from the National Influenza Pandemic Action Committee (NIPAC), the NDPSC reconsidered a proposal to reschedule oseltamivir from Schedule 4 to Schedule 3, and for inclusion in Appendix H. The NDPSC decided that the scheduling of oseltamivir remained appropriate. This decision was based on concerns regarding the likelihood of correct diagnosis by pharmacists without accurate point-of-care tests or physical examination during non-pandemic periods and concerns raised in regard to the then available inconclusive data relating to the likelihood of the development of resistance. In line with these concerns, the NDPSC acknowledged the need for the continued gathering of epidemiological data in relation to prevalence/resistance of influenza, which would be logistically difficult if oseltamivir was down-scheduled to Schedule 3. The NDPSC

Delegates’ reasons for interim decision
May 2013
Delegates’ reasons for interim decision
May 2013

wanted to see possible arrangements explored for appropriate access to oseltamivir should either a localised outbreak or an influenza pandemic occur.

In February 2006, following suggestion for rapid access to oseltamivir in extenuating circumstances, the NDPSC noted the legislative powers that exist at State and Territory level as well as activity at the Commonwealth level which would facilitate the supply of a Schedule 4 substance (such as oseltamivir) without a prescription during either a localised outbreak or an influenza pandemic.

In October 2006, the NDPSC considered a request from the New Zealand Medicines Classification Committee (NZ MCC) to harmonise the scheduling of oseltamivir with NZ. The NDPSC agreed that Australia was harmonised with NZ on the scheduling of oseltamivir given that the only change to the NZ classification was an exemption to do with supply of the medication and that such mechanisms of supply set down by jurisdictions had been duly explored at the February 2006 NDPSC meeting. Thus the NDPSC concluded that the scheduling of oseltamivir remained appropriate.

In October 2008, the NDPSC considered an application to reschedule oseltamivir from Schedule 4 to Schedule 3. The NDPSC decided that the scheduling of oseltamivir remained appropriate. The NDPSC remained concerned about the risk of the development of resistance, and that down-scheduling could potentially lower influenza vaccination rates, including among vulnerable patient groups. The NDPSC also noted that without appropriate physical examination the risk of misdiagnosis could lead to delays in treatment and potential exposure to adverse effects without the prospect of a significant benefit. The NDPSC expressed confidence that all States and Territories had established, or were planning to establish, mechanisms to facilitate rapid access to oseltamivir should circumstances warrant.

Scheduling status

Oseltamivir is included in Schedule 4.

Public pre-meeting submissions

Four public pre-meeting submissions were received.

Two submissions supported the proposal; one submission did not support the proposal; one submission indicated that while rescheduling has the potential to improve timely access to oseltamivir, there are concerns which may outweigh the benefit.


ACMS advice to the delegate

The ACMS recommended that the current scheduling of oseltamivir remains appropriate.

The matters under subsection 52E(1) of the Therapeutic Goods Act 1989 considered relevant by the ACMS include: (a) the risks and benefits of the use of a substance, and (f) other matters considered necessary to protect public health.

The reasons for the recommendation comprise of the following:

- Concern about the potential for increased resistance with widespread use.
Concern about misdiagnosis in the context that a doctor would be able to follow-up laboratory tests and improve surveillance.

Risk of reduced level of laboratory surveillance of influenza in the absence of medical prescribing.

Arrangements exist within the jurisdictions for access to oseltamivir during influenza pandemic situations.

Delegates consideration

The delegate considered the following in regards to this proposal:

- scheduling proposal;
- public submissions received;
- the evaluation report (not publicly available);
- ACMS advice;
- section 52E of the *Therapeutic Goods Act 1989*;
- scheduling factors15;
- other relevant information.

Delegates interim decision

The delegate has made an interim decision that the current scheduling of oseltamivir remains appropriate.

The delegate decided that the relevant matters under section 52E (1) of the *Therapeutic Goods Act 1989* include (a) the risks and benefits of a substance and (f) any other matters that the Secretary considers necessary to protect public health.

The decision that the entry for oseltamivir remains appropriate as a Schedule 4 listing included the following reasons:

- the potential for increased resistance;
- the potential for misdiagnosis; and
- the potential for decreased laboratory surveillance in the absence of medical prescribing.

---